✨ Free AI Report
Immunocore Holdings plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Immunocore Holdings plc
Company Research

Immunocore Holdings plc: Business Overview, Financials & Competitive Analysis

Immunocore Holdings plc scores 7/10 on the AskCyborg Cyborg Score (Strong). First-to-market TCR therapy with expanding global commercialization and strong pipeline, but profitability depends on pipeline progression beyond single revenue source. In 2024, Immunocore Holdings's revenue was $310.20 million, an increase of 24.37% compared to the previous year's $249.43 million. While KIMMTRAK sales have supported the company, they have not.

What is Immunocore Holdings plc's industry? Immunocore Holdings plc (immunocore.com) operates in Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy. AskCyborg classifies Immunocore Holdings plc under Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy in its company registry.

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. The company is pioneering and delivering transformative im...

7/ 10Strong

Cyborg Score thesis

First-to-market TCR therapy with expanding global commercialization and strong pipeline, but profitability depends on pipeline...

Read the full analyst-debate transcript →
Industry Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Immunocore Holdings plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Immunocore Holdings plc

AskCyborg analysts argue the bull and bear cases for Immunocore Holdings plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Immunocore Holdings plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Immunocore Holdings plc Overview

Pro stress-test →

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. The company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune diseases. The company represents a transformative approach to cell therapy with clinical validation and commercial traction.

Strategic Profile

Pro stress-test →

Built on its proprietary ImmTAX platform, the company has a diverse pipeline of bispecific therapies, with the platform modular allowing regulation of the immune system to tackle cancer (ImmTAC) or infectious diseases (ImmTAV), and downregulate it to address autoimmune conditions (ImmTAAI). Immunocore's strategic commercialization of its flagship KIMMTRAK with launches in 30 countries including key markets like the United States, Germany, and France, reflects plans for geographic expansion and patient reach enhancement.

Competitive Landscape

Pro stress-test →

Immunocore commercialized the world's first approved TCR therapy. The competitive landscape in TCR immunotherapy includes other cell therapy developers and checkpoint inhibitor manufacturers. Competitors include Adaptimmune (ADAP) with its own TCR program, Juno Therapeutics (Celgene/BMS) in CAR-T, and traditional oncology players like Merck and BMS. Immunocore's first-mover advantage and modular platform provide differentiation.

Industry Context

Immunocore Holdings plc operates in Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy.

Key facts

Founded: 1999 · Headquarters: Abingdon, United Kingdom · Employees: 524 · Revenue: $310.2M (2024) · Market cap: $1.5B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Immunocore Holdings plc.

  • KIMMTRAK has been approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma (mUM).
  • Key pipeline assets include IMC-R117C in Phase 1/2 for advanced solid tumors, IMC-M113V in Phase 1 for potential HIV functional cure, and IMC-I109V in Phase 1 for potential HBV functional cure.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Filed 10-K with detailed financial statements and strategic direction
  • Q3 2025KIMMTRAK net revenues of $103.7 million, growing 29% year-over-year
  • +1 moreTrack every material event for Immunocore Holdings plc as it happens. Explore monitoring →
Get alerted when Immunocore Holdings plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T therapy programsCAR-T cell therapy for oncology→TCR therapy programsT-cell receptor immunotherapy development→Checkpoint inhibitors and melanoma therapiesTraditional oncology immunotherapies→

Compare Immunocore Holdings plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Immunocore Holdings plc operates in Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Immunocore Holdings plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Immunocore Holdings plc and its top competitor on Cyborg Score”
“What did Immunocore Holdings plc do this quarter?”
“Is Immunocore Holdings plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Immunocore Holdings plc do?+
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. The company is pioneering and delivering transformative im...
What is Immunocore Holdings plc's Cyborg Score?+
Immunocore Holdings plc has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Immunocore Holdings plc's main competitors?+
Named competitors include CAR-T therapy programs, TCR therapy programs, Checkpoint inhibitors and melanoma therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Immunocore Holdings plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Immunocore Holdings plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Immunocore Holdings plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score